HIV-1 neutralization: Mechanisms and relevance to vaccine design

被引:41
作者
Zwick, Michael B. [1 ]
Burton, Dennis R. [1 ]
机构
[1] Scripps Res Inst, Dept Immunol, IMM 2, La Jolla, CA 92037 USA
关键词
neutralization mechanism; antibodies; vaccine development; virus fusion;
D O I
10.2174/157016207782418443
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antibody (Ab) mediated neutralization is a crucial means of host resistance to many pathogens and will most likely be required in the development of a vaccine to protect against HIV-1. Here we examine mechanistic aspects of HIV-1 neutralization with attention to recent Studies on the stoichiometric, kinetic and thermodynamic parameters involved. Neutralization of HIV-1, as with any microbe, minimally requires an initial molecular encounter with Ab. Ab occupancy of functional heterotrimers of the envelope glycoproteins, gp120 and gp41 (Env), indeed appears to be the dominant mechanism of neutralization for HIV-1. However, the Ab-binding site, the parameters mentioned above, as well as the stages and duration of vulnerability to Ab recognition, prior to and leading up to viral entry, each have a distinct impact on the mechanism of neutralization for any given Ab specificity. With HIV-1, the problems of mutational variation and neutralization resistance, coupled with the lability and conformational heterogeneity in Env, have stimulated the search for rational approaches to Env immunogen design that are unprecedented in vaccinology.
引用
收藏
页码:608 / 624
页数:17
相关论文
共 192 条
  • [61] Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses
    Karlsson, GB
    Gao, F
    Robinson, J
    Hahn, B
    Sodroski, J
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (09) : 6136 - 6142
  • [62] Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands
    Ketas, Thomas J.
    Kuhmann, Shawn E.
    Palmer, Ashley
    Zurita, Juan
    He, Weijing
    Ahuja, Sunil K.
    Klasse, Per Johan
    Moore, John P.
    [J]. VIROLOGY, 2007, 364 (02) : 281 - 290
  • [63] Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
    Kim, Mikyung
    Qiao, Zhisong
    Yu, Jessica
    Montefiori, David
    Reinherz, Ellis L.
    [J]. VACCINE, 2007, 25 (27) : 5102 - 5114
  • [64] Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies
    Kim, YB
    Han, DP
    Cao, C
    Cho, MW
    [J]. VIROLOGY, 2003, 305 (01) : 124 - 137
  • [65] Antibodies to west nile virus: A double-edged sword
    Klasse, Per Johan
    Burton, Dennis R.
    [J]. CELL HOST & MICROBE, 2007, 1 (02) : 87 - 89
  • [66] Occupancy and mechanism in anti body-mediated neutralization of animal viruses
    Klasse, PJ
    Sattentau, QJ
    [J]. JOURNAL OF GENERAL VIROLOGY, 2002, 83 : 2091 - 2108
  • [67] AN IMMUNE-SELECTED POINT MUTATION IN THE TRANSMEMBRANE PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HXB2-ENV-ALA 582(-] THR)) DECREASES VIRAL NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO THE CD4-BINDING SITE
    KLASSE, PJ
    MCKEATING, JA
    SCHUTTEN, M
    REITZ, MS
    ROBERTGUROFF, M
    [J]. VIROLOGY, 1993, 196 (01) : 332 - 337
  • [68] V3 VARIABILITY CAN INFLUENCE THE ABILITY OF AN ANTIBODY TO NEUTRALIZE OR ENHANCE INFECTION BY DIVERSE STRAINS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    KLIKS, SC
    SHIODA, T
    HAIGWOOD, NL
    LEVY, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11518 - 11522
  • [69] HIV vaccine design: insights from live attenuated SIV vaccines
    Koff, WC
    Johnson, PR
    Watkins, DI
    Burton, DR
    Lifson, JD
    Hasenkrug, KJ
    McDermott, AB
    Schultz, A
    Zamb, TJ
    Boyle, R
    Desrosiers, RC
    [J]. NATURE IMMUNOLOGY, 2006, 7 (01) : 19 - 23
  • [70] Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1)
    Kwong, PD
    Wyatt, R
    Desjardins, E
    Robinson, J
    Culp, JS
    Hellmig, BD
    Sweet, RW
    Sodroski, J
    Hendrickson, WA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (07) : 4115 - 4123